These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 34743223)
1. Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. Chu X; Qiang H; Xie M; Li X; Zhao J; Wu Y; Zhou J; Ye J; Zhao C; Han C; Chu T; Su C Cancer Immunol Immunother; 2022 Jul; 71(7):1625-1631. PubMed ID: 34743223 [TBL] [Abstract][Full Text] [Related]
2. The efficacy of immune checkpoint inhibitors in advanced Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y Front Immunol; 2022; 13():975246. PubMed ID: 36159795 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645 [TBL] [Abstract][Full Text] [Related]
4. A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Wang L; Wu Y; Ren Z; Chu X; Chen J; Liu L; Zhao J; Yu X; Xie M; Su C Cancer Med; 2024 Jun; 13(12):e7335. PubMed ID: 38923311 [TBL] [Abstract][Full Text] [Related]
5. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785 [TBL] [Abstract][Full Text] [Related]
7. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer. Xie M; Yu X; Chu X; Xie H; Zhou J; Zhao J; Su C Thorac Cancer; 2022 Feb; 13(3):353-360. PubMed ID: 34962050 [TBL] [Abstract][Full Text] [Related]
8. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070 [TBL] [Abstract][Full Text] [Related]
9. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study. Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182 [TBL] [Abstract][Full Text] [Related]
10. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y Front Immunol; 2022; 13():931718. PubMed ID: 35990690 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC. Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations. Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer]. Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161 [No Abstract] [Full Text] [Related]
14. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study. Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study. Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. Zhou S; Ren F; Meng X Front Immunol; 2022; 13():955944. PubMed ID: 36238280 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience. Bai M; Wang W; Gao X; Wu L; Jin P; Wu H; Yu J; Meng X Front Immunol; 2022; 13():832419. PubMed ID: 35296087 [TBL] [Abstract][Full Text] [Related]
20. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data. Yan N; Zhang H; Shen S; Guo S; Li X BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]